Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I
DEA places four synthetic cannabinoids (4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, MMB-FUBICA) into Schedule I, making them illegal to manufacture, distribute, or possess without DEA authorization.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 16, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. All pharmaceutical manufacturers, API/contract manufacturers, and compounding outsourcing facilities (503B) that handle or may encounter these substances. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Effective upon publication in the Federal Register (May 1, 2026). Immediate compliance required.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
These four substances are now classified as Schedule I controlled substances, with no accepted medical use and high abuse potential.
Who it affects
All pharmaceutical manufacturers, API/contract manufacturers, and compounding outsourcing facilities (503B) that handle or may encounter these substances.
What you must do
Immediately cease any production, distribution, or possession of these substances; review inventory and supply chains; notify DEA if any are present; and ensure no further handling without a Schedule I research registration.
Deadline
Effective upon publication in the Federal Register (May 1, 2026). Immediate compliance required.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- IL HB0004: MEDICAID-PHARMACY SERVICES
- Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
- Determination That RECTIV (Nitroglycerin) Ointment, 0.4%, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Determination That Prednisolone Tablet, 5 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Determination That VASOPRESSIN IN SODIUM CHLORIDE (vasopressin) 0.9%, Injection, 50 units/50 milliliters (1 unit/milliliters) Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness